- Home
- PETZ vs GTBP Comparison
PETZ vs GTBP Comparison
Compare PETZ & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | GTBP |
|---|---|---|
| Founded | 2002 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.0M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PETZ | GTBP |
|---|---|---|
| Price | $1.31 | $7.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 388.9K | 341.5K |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.22 |
| 52 Week High | $1.83 | $11.98 |
Technical Indicators
Market Signals| Indicator | PETZ | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 65.87 |
| Support Level | $1.01 | $0.36 |
| Resistance Level | $1.81 | N/A |
| Average True Range (ATR) | 0.13 | 1.07 |
| MACD | 0.00 | 0.49 |
| Stochastic Oscillator | 38.06 | 59.43 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.